HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) All Versions of this Article: 0091270009337132v1 49/7/782    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Xiaoli, D. Articles by Qiang, F. Search for Related Content PubMed PubMed Citation Articles by Xiaoli, D. Articles by Qiang, F. Social Bookmarking                         What's this?

Population Pharmacokinetic Study of Cyclosporine in Patients With Nephrotic Syndrome

From the Pharmacy Department, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.

Cyclosporine (CsA) is widely used in the treatment of nephrotic syndrome (NS). A population pharmacokinetic (PopPK) model was developed using trough blood CsA concentration data from 106 patients with NS. The pharmacokinetic analysis was performed using NONMEM with 1-compartment linear model and first-order elimination. Proportional and additive error models were used to describe the interindividual and intraindividual variabilities, respectively. Body weight (WT), serum albumin level (ALB), and combination therapy with rifampicin were found to be the most significant covariates explaining the variability of the apparent clearance (CL/F) of CsA among patients. The final model was as follows: TVCL/F = 34.1 x (WT/67.6)^1.08 x (1 + RFA x 0.67) x (1 – ALB x 0.0088); TVV/F = 3.5 x WT; Ka = 1.28 fixed; where RFA = 1 with concurrent rifampicin use and 0 otherwise. The interindividual variabilities of CL/F and V/F were 18% and 27%, respectively. The residual error was 0.064 mg/L. The mean ± SD of CL/F and V/F of the 106 patients were 23.5 ± 7.2 L/h and 232.3 ± 71.5 L, respectively. The reliability and stability of the PopPK model were confirmed by nonparametric bootstrap procedure.

Key Words: Cyclosporine • population pharmacokinetics • nephrotic syndrome • NONMEM • Bayesian estimation

Address for reprints: Du Xiaoli, MS, Pharmacy Department, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, #1 Shuaifuyuan, Beijing 100730, China.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?